• 1
    Teo P, Yu P, Lee WY, et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinomas evaluated by computer tomography. Int J Radiat Oncol Biol Phys. 1996; 36: 291-304.
  • 2
    Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23: 261-270.
  • 3
    Fandi A, Altun M, Azli N, et al. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994; 21: 382-397.
  • 4
    Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the naso-pharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997; 37: 985-996.
  • 5
    Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005; 23: 1118-1124.
  • 6
    Zidan J, Kuten A, Robinson E. Intensive short cause chemotherapy followed by radiotherapy of locally advanced nasopharyngeal carcinoma. Cancer. 1996; 77: 1973-1977.
  • 7
    Kuo WR, Lee KW, Ching FY, Jan YS, Juan KH. The effect of adjuvant chemotherapy for nasopharyngeal carcinoma: a preliminary report. Gaoxiong Yi Xue Ke Xue Za Zhi. 1993; 9: 9-17.
  • 8
    El-Weshi A, Khafaga Y, Allam A, et al. Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma—a phase II study. Acta Oncol. 2001; 40: 574-581.
  • 9
    Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005; 103: 850-857.
  • 10
    Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989; 58: 137-171.
  • 11
    Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30: 301-311.
  • 12
    West DJ, Najm YC, Mistry R, et al. The localization of myocardial ischemia with technetium-99m-methoxyisobutyl-isonitrile and single photon emission computed tomography. Br J Radiol. 1989; 62: 303-313.
  • 13
    Fujii H, Nakamura K, Kubo A, et al. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res. 1998; 18: 4601-4605.
  • 14
    Ceriani L, Giovanella L, Bandera M, et al. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun. 1997; 18: 1087-1097.
  • 15
    Yamamoto Y, Nishiyama Y, Satoh K, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med. 1998; 39: 1626-1629.
  • 16
    Bom HS, Kim YC, Song HC, et al. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med. 1998; 39: 91-94.
  • 17
    Kim YS, Cho SW, Lee KJ, et al. Tc-99m-MIBI SPECT is useful for noninvasively predicting the response of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma. Clin Nucl Med. 1999; 24: 874-879.
  • 18
    Kao CH, Tsai SC, Wang JJ, et al. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factor. Br J Haematol. 2001; 113: 369-374.
  • 19
    Taki J, Sumiya H, Asada N, et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med. 1998; 39: 1179-1184.
  • 20
    Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2 methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med. 1990; 31: 1646-1653.
  • 21
    Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med. 1996; 37: 1551-1556.
  • 22
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
  • 23
    Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993; 53: 977-984.
  • 24
    Waxman AD. Thallium-201 and technetium-99m methoxyisobutyl isonitrile (MIBI) in nuclear oncology. In: SandlerMP, ColemanRE, WackersFJT, et al., eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore, Md: Williams and Wilkins; 1996: 1261-1274.
  • 25
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005; 23: 8636-8645.
  • 26
    Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704.
  • 27
    Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004; 22: 3053-3060.
  • 28
    Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Strahlenther Onkol. 2005; 181: 223-230.
  • 29
    McGrogan BT, Gilmartin B, Carney DN, et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008; 1785: 96-132.
  • 30
    Zhu X, Sui M, Fan W. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res. 2005; 25( 3B): 1953-1962.
  • 31
    Naito M, Matsuba Y, Sato S, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res. 2002; 8: 582-588.